• Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Home
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
Home
Subscribe
Hamburger Menu Hamburger Menu
  • Biotech
    • Cell & Gene Therapy
    • Clinical Data
    • Oncology
    • Venture Capital
    • Deals
  • Research
  • Medtech
    • Devices
    • Diagnostics
    • AI and Machine Learning
  • CRO
  • Special Reports
  • Trending
    • Biologics
    • Clinical Development
    • Ophthalmology
    • Cell & Gene Therapy
    • Drug Development
    • Small Molecule Research & Development
    • Oncology
  • Fierce 50
    • Special Report
    • Awards Gala
  • Awards
    • Outsourcing Awards
    • Innovation Awards
  • Resources
    • Fierce Events
    • Industry Events
    • Webinars
    • Podcasts
    • Whitepapers
    • Survey
  • Events
  • Subscribe
  • Fierce Pharma
  • Fierce Biotech
  • Fierce Healthcare
  • Fierce Life Sciences Events
  • Advertise
  • About Us
Bristol Myers Squibb booth at AACR 2026
Biotech

BMS doubles up with pivotal wins in lung disease, solid tumor

Bristol Myers Squibb has reported phase 3 wins in a lung disease and a solid tumor, taking two steps on its path toward post-patent cliff growth.
Nick Paul Taylor Oct 12, 2026 8:05am
iRegene Therapeuticss NouvSight001 Cleared for Clinical Trials in the US and China for Retinitis Pigmentosa

iRegene Therapeutics’s NouvSight001 Cleared for Clinical Trials in the U.S. and China for Retinitis Pigmentosa

Brought to you by iRegene Therapeutics
Merck  Co headquarters

Merck data raise fears $1.3B eye drug has ‘limited’ potential

Oct 12, 2026 2:54am
Stock market IPO share price

Parkinson’s-focused Aspen and bispecific biotech Aspen plan IPOs

Oct 12, 2026 2:00am
Roche ESMO

Roche sets sights on July FDA ruling with updated eye drug data

Oct 12, 2026 9:42am
Tortoise

Tortugas’ schizophrenia drug proves worth in ph. 2 Hansoh trial

Oct 12, 2026 9:23am
More News

GSK drinks in Chai’s AI models after wet-lab validation

Oct 9, 2026 10:36am

How Nobel-winning optogenetics is being harnessed by biotechs

Oct 9, 2026 9:30am

Vir looks to Liu to lead late-stage push—Chutes & Ladders

Oct 9, 2026 8:30am

How we picked the Fierce 15

Oct 9, 2026 7:21am
See more stories
Home
  • Connect
    • The Team
    • Advertise
    • Marketing Kit
    • Let's Talk
  • Join Us
    • Newsletters
    • Resources
    • RSS Feeds
  • Our Brands
    • Fierce Pharma
    • Fierce Biotech
    • Fierce Healthcare
  • Our Events
    • Life Sciences Events
©2026 Questex LLC All rights reserved.
Terms of use
Privacy Policy
Privacy Settings